Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT03127384 Completed - Healthy Volunteers Clinical Trials

Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars

Start date: April 20, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate performance and safety of Restylane Lidocaine for treatment of depressed facial acne scars

NCT ID: NCT03119181 Completed - Healthy Volunteer Clinical Trials

Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane

ADEPT
Start date: April 27, 2017
Phase: Phase 2
Study type: Interventional

A prospective, multicenter study to determine if active Tymbion iontophoresis is superior to sham Tymbion iontophoresis in providing anesthesia to the tympanic membrane (TM). The study will use the Tula iontophoresis systems for healthy adult volunteers in an office setting, called Group A of Protocol CPR007003. The protocol CPR007003 also includes a Group B study described in a separate Registration (NCT03197558).

NCT ID: NCT03118583 Completed - Healthy Volunteers Clinical Trials

Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers

Start date: March 15, 2017
Phase: N/A
Study type: Interventional

The goal of this study is to assess the effects of a dietary supplement on fasting lipoprotein lipids and a marker of inflammation in men and women with levels of low-density lipoprotein cholesterol above desirable levels.

NCT ID: NCT03115996 Completed - Healthy Volunteers Clinical Trials

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

Start date: May 10, 2017
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses and a multiple dose regimen.

NCT ID: NCT03113903 Completed - Healthy Volunteers Clinical Trials

Validation of the French Version of the Pain Sensitivity Questionnaire

PSQ-F
Start date: April 30, 2017
Phase: N/A
Study type: Interventional

The Pain Sensitivity Questionnaire (PSQ) is a tool created in 2009 by Dr. R. Ruscheweyh in Germany. It aims at identifying the natural sensitivity to pain, through a set of 17 simple questions. These questions simulate daily life situations likely to induce pain of various intensities. The internal validity of the tool had been demonstrated both for the original version in German, and then for its English version. The external validity had also been demonstrated by correlation to real nociceptive stimulations applied to healthy volunteers (German version), and to patients before surgery (English version). A French validation of the questionnaire is needed, in order to integrate it in pain research programs in French-speaking countries.

NCT ID: NCT03108755 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects

Start date: May 23, 2017
Phase: Phase 1
Study type: Interventional

This is a combined Single and Multiple Ascending Oral Dose Study. Part 1 is a Single Ascending Dose (SAD) and Part 2 is Multiple Ascending Dose (MAD). The purpose of the study is to evaluate the safety and tolerability of single and multiple ascending oral doses of ASP7713 in healthy non-Japanese (Part 1) and Japanese (Part 2) adult participants and non-Japanese elderly participants (Part 2). This study will also evaluate the pharmacokinetics of single and multiple ascending oral doses of ASP7713 in non-Japanese (Part1) and Japanese (Part 2) adult participants and non-Japanese elderly participants (Part 2) as well as the effect of a single and multiple oral dose of ASP7713 on the QT interval using Fridericia's Correction (QTcF). In addition, this study will evaluate a potential racial difference in safety, tolerability and pharmacokinetics of multiple oral doses of ASP7713 in healthy non-Japanese and Japanese adult participants (Part 2).

NCT ID: NCT03105375 Completed - Healthy Volunteers Clinical Trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study

Start date: February 21, 2017
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.

NCT ID: NCT03101878 Completed - Healthy Volunteers Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Start date: April 5, 2017
Phase: Phase 1
Study type: Interventional

The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS AGT-LRx in up to 82 Healthy Volunteers

NCT ID: NCT03101293 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Start date: April 4, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the pharmacokinetic (PK) of a single oral dose of TAK-831 400 milligram (mg) in the fasted state and to estimate the effect of food on the PK of a single oral dose of TAK-831 400 mg when administered as tablet formulation in healthy participants.

NCT ID: NCT03100838 Completed - Healthy Volunteers Clinical Trials

Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets

Start date: March 20, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to measure the amount of study drug present in blood after being administered a generic version of nifedipine extended-release tablets, 60 mg (Valeant Pharmaceuticals, LLC) and brand-name version PROCARDIA XL extended-release tablets, 60 mg (Pfizer Inc.) individually and in presence of stomach acid reducing drug (antacid), omeprazole/sodium bicarbonate capsules, 40 mg/1100 mg (generic) on separate occasions, on an empty stomach. This study also involves administrations of an FDA-cleared capsule, SmartPill™, which will measure stomach acid, prior to each study arm.